Top

Published in:

Open Access 01-06-2010

Why not treat human cancer with interleukin-1 blockade?

Author: Charles A. Dinarello

Published in: Cancer and Metastasis Reviews | Issue 2/2010

Abstract

The clinical successes of targeting angiogenesis provide a basis for trials of interleukin-1 (IL-1) blockade and particularly anti-IL-1β as an add-on therapy in human metastatic disease. In animal studies for over 20 years, IL-1 has been demonstrated to increase adherence of tumor cells to the endothelium in vitro, and administration of IL-1 to mice increases the number of metastatic colonies and tumor growth. Importantly, reducing endogenous IL-1 activity, particularly IL-1β, with the naturally occurring IL-1 receptor antagonist (IL-1Ra) reduces both metastasis as well as tumor burden. Inhibition of IL-1 activity prevents in vivo blood vessel formation induced by products released from hypoxic macrophages or vascular endothelial cell growth factor itself. Mice deficient in IL-1β do not form blood vessels in matrigels embedded with vascular endothelial cell growth factor or containing products of macrophages. Recombinant IL-1Ra (anakinra) has been administered to over 1,000 patients with septic shock resulting in a consistent reduction in all-cause 28-day mortality. Approved for treatment of rheumatoid arthritis, anakinra has a remarkable safety record. Anakinra resulted in decreased blood vessels in the pannus of affected joints in patients with rheumatoid arthritis. Neutralizing monoclonal antibodies to IL-1β and a soluble receptor to IL-1 are approved for treating chronic inflammatory diseases. Given the availability of three therapeutic agents for limiting IL-1 activity, the safety of blocking IL-1, and the clear benefit of blocking IL-1 activity in animal models of metastasis and angiogenesis, clinical trials of IL-1 blockade should be initiated, particularly as an add-on therapy of patients receiving antiangiogenesis-based therapies.

Balkwill, F., Charles, K. A., & Mantovani, A. (2005). Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell, 7, 211–217.PubMedCrossRef

Mantovani, A. (2005). Cancer: inflammation by remote control. Nature, 435, 752–753.PubMedCrossRef

Krelin, Y., Voronov, E., Dotan, S., Elkabets, M., Reich, E., Fogel, M., et al. (2007). Interleukin-1beta-driven inflammation promotes the development and invasiveness of chemical carcinogen-induced tumors. Cancer Research, 67, 1062–1071.PubMedCrossRef

El-Omar, E. M., Carrington, M., Chow, W. H., McColl, K. E., Bream, J. H., Young, H. A., et al. (2001). The role of interleukin-1 polymorphisms in the pathogenesis of gastric cancer. Nature, 412, 99.PubMedCrossRef

Glas, J., Torok, H. P., Schneider, A., Brunnler, G., Kopp, R., Albert, E. D., et al. (2004). Allele 2 of the interleukin-1 receptor antagonist gene is associated with early gastric cancer. Journal of Clinical Oncology, 22, 4746–4752.PubMedCrossRef

Hamajiama, N., Matsuo, K., Saito, T., Tajima, K., Okujma, K., Yamao, K., et al. (2001). Interleukin-1 polymorphims, lifestyle factors and Helicobacter pylori infection. Japanese Journal of Cancer Research, 92, 383–389.

Riedel, S., Kraft, M., Kucharzik, T., Pauels, H. G., Tiemann, M., Steinbuchel, A., et al. (2001). CD4+ Th1-cells predominate in low-grade B-cell lymphoma of gastric mucosa-associated lymphoid tissue (MALT type). Scandinavian Journal of Gastroenterology, 36, 1198–1203.PubMedCrossRef

Gatti, L. L., Burbano, R. R., de Assumpcao, P. P., Smith, M. A., & Payao, S. L. (2004). Interleukin-1beta polymorphisms. Helicobacter pylori infection in individuals from Northern Brazil with gastric adenocarcinoma. Clinical and Experimental Medicine, 4, 93–98.PubMedCrossRef

Chang, Y. W., Jang, J. Y., Kim, N. H., Lee, J. W., Lee, H. J., Jung, W. W., et al. (2005). Interleukin-1B (IL-1B) polymorphisms and gastric mucosal levels of IL-1beta cytokine in Korean patients with gastric cancer. International Journal of Cancer, 114, 465–471.CrossRef

10.

Germano, G., Allavena, P., & Mantovani, A. (2008). Cytokines as a key component of cancer-related inflammation. Cytokine, 43, 374–379.PubMedCrossRef

11.

Lust, J. A., Lacy, M. Q., Zeldenrust, S. R., Dispenzieri, A., Gertz, M. A., Witzig, T. E., et al. (2009). Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1{beta}-induced interleukin 6 production and the myeloma proliferative component. Mayo Clinic Proceedings, 84, 114–122.PubMedCrossRef

12.

Vidal-Vanaclocha, F., Alvarez, A., Asumendi, A., Urcelay, B., Tonino, P., & Dinarello, C. A. (1996). Interleukin 1 (IL-1)-dependent melanoma hepatic metastasis in vivo; increased endothelial adherence by IL-1-induced mannose receptors and growth factor production in vitro. Journal of the National Cancer Institute, 88, 198–205.PubMedCrossRef

13.

Lewis, A. M., Varghese, S., Xu, H., & Alexander, H. R. (2006). Interleukin-1 and cancer progression: the emerging role of interleukin-1 receptor antagonist as a novel therapeutic agent in cancer treatment. Journal of Translational Medicine, 4, 48.PubMedCrossRef

14.

Giavazzi, R., Garofalo, A., Bani, M. R., Abbate, M., Ghezzi, P., Boraschi, D., et al. (1990). Interleukin 1-induced augmentation of experimental metastases from a human melanoma in nude mice. Cancer Research, 50, 4771–4775.PubMed

15.

Lauri, D., Bertomeu, M. C., Orr, F. W., Bastida, E., Sauder, D., & Buchanan, M. R. (1990). Interleukin-1 increases tumor cell adhesion to endothelial cells through an RGD dependent mechanism: in vitro and in vivo studies. Clinical & Experimental Metastasis, 8, 27–32.CrossRef

16.

Arguello, F., Baggs, R. B., Graves, B. T., Harwell, S. E., Cohen, H. J., & Frantz, C. N. (1992). Effect of IL-1 on experimental bone/bone-marrow metastases. International Journal of Cancer, 52, 802–807.CrossRef

17.

Mannel, D. N., Orosz, P., Hafner, M., & Falk, W. (1994). Mechanisms involved in metastasis enhanced by inflammatory mediators. Circulatory Shock, 44, 9–13.PubMed

18.

Scherbarth, S., & Orr, F. W. (1997). Intravital videomicroscopic evidence for regulation of metastasis by the hepatic microvasculature: effects of interleukin-1alpha on metastasis and the location of B16F1 melanoma cell arrest. Cancer Research, 57, 4105–4110.PubMed

19.

Chirivi, R. G., Chiodoni, C., Musiani, P., Garofalo, A., Bernasconi, S., Colombo, M. P., et al. (1996). IL-1alpha gene-transfected human melanoma cells increase tumor-cell adhesion to endothelial cells and their retention in the lung of nude mice. International Journal of Cancer, 67, 856–863.CrossRef

20.

Khatib, A. M., Kontogiannea, M., Fallavollita, L., Jamison, B., Meterissian, S., & Brodt, P. (1999). Rapid induction of cytokine and E-selectin expression in the liver in response to metastatic tumor cells. Cancer Research, 59, 1356–1361.PubMed

21.

Vidal-Vanaclocha, F., Amezaga, C., Asumendi, A., Kaplanski, G., & Dinarello, C. A. (1994). Interleukin-1 receptor blockade reduces the number and size of murine B16 melanoma hepatic metastases. Cancer Research, 54, 2667–2672.PubMed

22.

Martin-Padura, I., Mortarini, R., Lauri, D., Bernasconi, S., Sanchez-Madrid, F., Parmiani, G., et al. (1991). Heterogeneity in human melanoma cell adhesion to cytokine activated endothelial cells correlates with VLA-4 expression. Cancer Research, 51, 2239–2241.PubMed

23.

Garofalo, A., Chirivi, R. G., Foglieni, C., Pigott, R., Mortarini, R., Martin-Padura, I., et al. (1995). Involvement of the very late antigen 4 integrin on melanoma in interleukin 1-augmented experimental metastases. Cancer Research, 55, 414–419.PubMed

24.

Dinarello, C. A. (2009). Immunological and inflammatory functions of the interleukin-1 family. Ann Rev Immunol, 27, 519–550.CrossRef

25.

Okamoto, M., Liu, W., Luo, Y., Tanaka, A., Cai, X., Norris, D. A., et al. (2009). Constitutively active inflammasome in human melanoma cells mediating autoinflammation via caspase-1 processing and secretion of interleukin-1beta. The Journal of Biological Chemistry, 285, 6477–6488.PubMedCrossRef

26.

Song, X., Voronov, E., Dvorkin, T., Fima, E., Cagnano, E., Benharroch, D., et al. (2003). Differential effects of IL-1alpha and IL-1beta on tumorigenicity patterns and invasiveness. Journal of Immunology, 171, 6448–6456.

27.

Chirivi, R. G., Garofalo, A., Padura, I. M., Mantovani, A., & Giavazzi, R. (1993). Interleukin 1 receptor antagonist inhibits the augmentation of metastasis induced by interleukin 1 or lipopolysaccharide in a human melanoma/nude mouse system. Cancer Research, 53, 5051–5054.PubMed

28.

Weinreich, D. M., Elaraj, D. M., Puhlmann, M., Hewitt, S. M., Carroll, N. M., Feldman, E. D., et al. (2003). Effect of interleukin 1 receptor antagonist gene transduction on human melanoma xenografts in nude mice. Cancer Research, 63, 5957–5961.PubMed

29.

Elaraj, D. M., Weinreich, D. M., Varghese, S., Puhlmann, M., Hewitt, S. M., Carroll, N. M., et al. (2006). The role of interleukin 1 in growth and metastasis of human cancer xenografts. Clinical Cancer Research, 12, 1088–1096.PubMedCrossRef

30.

Voronov, E., Shouval, D. S., Krelin, Y., Cagnano, E., Benharroch, D., Iwakura, Y., et al. (2003). IL-1 is required for tumor invasiveness and angiogenesis. Proceedings of the National Academy of Sciences of the United States of America, 100, 2645–2650.PubMedCrossRef

31.

Carmi, Y., Voronov, E., Dotan, S., Lahat, N., Rahat, M. A., Fogel, M., et al. (2009). The role of macrophage-derived IL-1 in induction and maintenance of angiogenesis. Journal of Immunology, 183, 4705–4714.CrossRef

32.

Coxon, A., Bolon, B., Estrada, J., Kaufman, S., Scully, S., Rattan, A., et al. (2002). Inhibition of interleukin-1 but not tumor necrosis factor suppresses neovascularization in rat models of corneal angiogenesis and adjuvant arthritis. Arthritis and Rheumatism, 46, 2604–2612.PubMedCrossRef

33.

Cunnane, G., Madigan, A., Murphy, E., FitzGerald, O., & Bresnihan, B. (2001). The effects of treatment with interleukin-1 receptor antagonist on the inflamed synovial membrane in rheumatoid arthritis. Rheumatology (Oxford), 40, 62–69.CrossRef

34.

Towbin, H., Schmitz, A., van Oostrum, J., Seitz, M., Dewald, B., Zingel, O., et al. (1994). Monoclonal antibody based enzyme-linked and chemiluminescent assays for the human interleukin-1 receptor antagonist. Application to measure hIL-1ra levels in monocyte cultures and synovial fluids. Journal of Immunological Methods, 170, 125–135.PubMedCrossRef

35.

Dossus, L., Becker, S., Achaintre, D., Kaaks, R., & Rinaldi, S. (2009). Validity of multiplex-based assays for cytokine measurements in serum and plasma from “non-diseased” subjects: comparison with ELISA. Journal of Immunological Methods, 350, 125–132.PubMedCrossRef

36.

Lachmann, H. J., Lowe, P., Felix, S. D., Rordorf, C., Leslie, K., Madhoo, S., et al. (2009). In vivo regulation of interleukin 1beta in patients with cryopyrin-associated periodic syndromes. The Journal of Experimental Medicine, 206, 1029–1036.PubMedCrossRef

37.

Granowitz, E. V., Santos, A., Poutsiaka, D. D., Cannon, J. G., Wilmore, D. A., Wolff, S. M., et al. (1991). Circulating interleukin-1 receptor antagonist levels during experimental endotoxemia in humans. Lancet, 338, 1423–1424.PubMedCrossRef

38.

Fischer, E., van Zee, K. J., Marano, M. A., Rock, C. S., Kenney, J. S., Poutsiaka, D. D., et al. (1992). Interleukin-1 receptor antagonist circulates in experimental inflammation and in human disease. Blood, 79, 2196–2200.PubMed

39.

Kopp, W. C., Urba, W. J., Rager, H. C., Alvord, W. G., Oppenheim, J. J., Smith, J. W., 2nd, et al. (1996). Induction of interleukin 1 receptor antagonist after interleukin 1 therapy in patients with cancer. Clinical Cancer Research, 2, 501–506.PubMed

40.

Atkins, M. B., Vachino, G., Tilg, H. J., Karp, D. D., Robert, N. J., Kappler, K., et al. (1992). Phase I evaluation of thrice-daily intravenous bolus interleukin-4 in patients with refractory malignancy. Journal of Clinical Oncology, 10, 1802–1809.PubMed

41.

Gabay, C., Smith, M. F., Eidlen, D., & Arend, W. P. (1997). Interleukin 1 receptor antagonist (IL-1Ra) is an acute-phase protein. Journal of Clinical Investigation, 99, 2930–2940.PubMedCrossRef

42.

Lamacchia, C., Palmer, G., Seemayer, C. A., Talabot-Ayer, D., & Gabay, C. (2010). Enhanced Th1 and Th17 responses and arthritis severity in mice with a deficiency of myeloid cell-specific interleukin-1 receptor antagonist. Arthritis and Rheumatism, 62, 452–462.PubMed

43.

Fuksiewicz, M., Kaminska, J., Kotowicz, B., Kowalska, M., Rubach, M., & Pienkowski, T. (2006). Serum cytokine levels and the expression of estrogen and progesterone receptors in breast cancer patients. Clinical Chemistry and Laboratory Medicine, 44, 1092–1097.PubMedCrossRef

44.

Hu, Z., Shao, M., Chen, Y., Zhou, J., Qian, J., Xu, L., et al. (2006). Allele 2 of the interleukin-1 receptor antagonist gene (IL1RN*2) is associated with a decreased risk of primary lung cancer. Cancer Letters, 236, 269–275.PubMedCrossRef

45.

Rafiq, S., Stevens, K., Hurst, A. J., Murray, A., Henley, W., Weedon, M. N., et al. (2007). Common genetic variation in the gene encoding interleukin-1-receptor antagonist (IL-1RA) is associated with altered circulating IL-1RA levels. Genes and Immunity, 8, 344–351.PubMedCrossRef

46.

Graziano, F., Ruzzo, A., Canestrari, E., Loupakis, F., Santini, D., Rulli, E., et al. (2009). Variations in the interleukin-1 receptor antagonist gene impact on survival of patients with advanced colorectal cancer. The Pharmacogenomics Journal, 9, 78–84.PubMedCrossRef

47.

Rambaldi, A., Torcia, M., Bettoni, S., Barbui, T., Vannier, E., Dinarello, C. A., et al. (1991). Modulation of cell proliferation and cytokine production in acute myeloblastic leukemia by interleukin-1 receptor antagonist and lack of its expression by leukemic cells. Blood, 78, 3248–3253.PubMed

48.

Estrov, Z., Kurzrock, R., Estey, E., Wetzler, M., Kantarjian, H., Blake, M., et al. (1992). Inhibition of acute myelogenous leukemia proliferation by IL-1 receptor antagonist and soluble IL-1 receptors. Blood, 79, 1938–1945.PubMed

49.

Kurzrock, R. (2001). Cytokine deregulation in cancer. Biomedicine & Pharmacotherapy, 55, 543–547.CrossRef

50.

Ferretti, M., Casini-Raggi, V., Pizarro, T. T., Eisenberg, S. P., Nast, C. C., & Cominelli, F. (1994). Neutralization of endogenous IL-1 receptor antagonist exacerbates and prolongs inflammation in rabbit immune colitis. Journal of Clinical Investigation, 94, 449–453.PubMedCrossRef

51.

Horai, R., Saijo, S., Tanioka, H., Nakae, S., Sudo, K., Okahara, A., et al. (2000). Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist-deficient mice. The Journal of Experimental Medicine, 191, 313–320.PubMedCrossRef

52.

Nicklin, M. J., Hughes, D. E., Barton, J. L., Ure, J. M., & Duff, G. W. (2000). Arterial inflammation in mice lacking the interleukin 1 receptor antagonist gene. The Journal of Experimental Medicine, 191, 303–312.PubMedCrossRef

53.

Larsen, C. M., Faulenbach, M., Vaag, A., Ehses, J. A., Donath, M. Y., & Mandrup-Poulsen, T. (2009). Sustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes. Diabetes Care, 32, 1663–1668.PubMedCrossRef

54.

Aksentijevich, I., Masters, S. L., Ferguson, P. J., Dancey, P., Frenkel, J., van Royen-Kerkhoff, A., et al. (2009). An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist. The New England Journal of Medicine, 360, 2426–2437.PubMedCrossRef

55.

Reddy, S., Jia, S., Geoffrey, R., Lorier, R., Suchi, M., Broeckel, U., et al. (2009). An autoinflammatory disease due to homozygous deletion of the IL1RN locus. The New England Journal of Medicine, 360, 2438–2444.PubMedCrossRef

56.

Pascual, V., Allantaz, F., Arce, E., Punaro, M., & Banchereau, J. (2005). Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. The Journal of Experimental Medicine, 201, 1479–1486.PubMedCrossRef

57.

Goldbach-Mansky, R., Dailey, N. J., Canna, S. W., Gelabert, A., Jones, J., Rubin, B. I., et al. (2006). Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition. The New England Journal of Medicine, 355, 581–592.PubMedCrossRef

58.

Gattorno, M., Tassi, S., Carta, S., Delfino, L., Ferlito, F., Pelagatti, M. A., et al. (2007). Pattern of interleukin-1beta secretion in response to lipopolysaccharide and ATP before and after interleukin-1 blockade in patients with CIAS1 mutations. Arthritis and Rheumatism, 56, 3138–3148.PubMedCrossRef

59.

Kyle, R. A., Remstein, E. D., Therneau, T. M., Dispenzieri, A., Kurtin, P. J., Hodnefield, J. M., et al. (2007). Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. The New England Journal of Medicine, 356, 2582–2590.PubMedCrossRef

60.

Torcia, M., Lucibello, M., Vannier, E., Fabiani, S., Miliani, A., Guidi, G., et al. (1996). Modulation of osteoclast-activating factor activity of multiple myeloma bone marrow cells by different interleukin-1 inhibitors. Experimental Hematology, 24, 868–874.PubMed

61.

Lust, J. A., & Donovan, K. A. (1999). The role of interleukin-1 beta in the pathogenesis of multiple myeloma. Hematology/Oncology Clinics of North America, 13, 1117–1125.PubMedCrossRef

62.

Bar, D., Apte, R. N., Voronov, E., Dinarello, C. A., & Cohen, S. (2004). A continuous delivery system of IL-1 receptor antagonist reduces angiogenesis and inhibits tumor development. The FASEB Journal, 18, 161–163.PubMed

63.

Olson, J. L., Courtney, R. J., Rouhani, B., Mandava, N., & Dinarello, C. A. (2009). Intravitreal anakinra inhibits choroidal neovascular membrane growth in a rat model. Ocular Immunology and Inflammation, 17, 195–200.PubMedCrossRef

64.

Apte, R. N., Dotan, S., Elkabets, M., White, M. R., Reich, E., Carmi, Y., et al. (2006). The involvement of IL-1 in tumorigenesis, tumor invasiveness, metastasis and tumor-host interactions. Cancer and Metastasis Reviews, 25, 387–408.PubMedCrossRef

65.

Song, X., Krelin, Y., Dvorkin, T., Bjorkdahl, O., Segal, S., Dinarello, C. A., et al. (2005). CD11b+/Gr-1+ immature myeloid cells mediate suppression of T cells in mice bearing tumors of IL-1β-secreting Cells. Journal of Immunology, 175, 8200–8208.

66.

Zoller, M., Douvdevani, A., Segal, S., & Apte, R. N. (1992). Interleukin-1 production by transformed fibroblasts. II. Influence on antigen presentation and T-cell-mediated anti-tumor response. International Journal of Cancer, 50, 450–457.CrossRef

67.

Colombo, M. P., & Mantovani, A. (2005). Targeting myelomonocytic cells to revert inflammation-dependent cancer promotion. Cancer Research, 65, 9113–9116.PubMedCrossRef

68.

Cohen, I., Rider, P., Carmi, Y., Braiman, A., Dotan, S., White, M. R., et al. (2010). Differential release of chromatin-bound IL-1alpha discriminates between necrotic and apoptotic cell death by the ability to induce sterile inflammation. Proceedings of the National Academy of Sciences of the United States of America, 107, 2574–2579.PubMedCrossRef

69.

Larsen, C. M., Faulenbach, M., Vaag, A., Volund, A., Ehses, J. A., Seifert, B., et al. (2007). Interleukin-1-receptor antagonist in type 2 diabetes mellitus. The New England Journal of Medicine, 356, 1517–1526.PubMedCrossRef

70.

Donath, M. Y., Weder, C., Brunner, A., Keller, C., Whitemore, J., Der, K., et al. (2009). XOMA 052, a potential disease modifying anti-1L-1beta antibody, shows sustained HbA1c reductions 3 Months after a single injection with no increases in safety parameters in subjects with Type 2 diabetes. Diabetes, 58, A30.CrossRef

71.

Lachmann, H. J., Kone-Paut, I., Kuemmerle-Deschner, J. B., Leslie, K. S., Hachulla, E., Quartier, P., et al. (2009). Use of canakinumab in the cryopyrin-associated periodic syndrome. New England Journal of Medicine, 360, 2416–2425.PubMedCrossRef

72.

Hoffman, H. M., Throne, M. L., Amar, N. J., Sebai, M., Kivitz, A. J., Kavanaugh, A., et al. (2008). Efficacy and safety of rilonacept (interleukin-1 trap) in patients with cryopyrin-associated periodic syndromes: Results from two sequential placebo-controlled studies. Arthritis and Rheumatism, 58, 2443–2452.PubMedCrossRef

73.

Jain, R. K., Duda, D. G., Clark, J. W., & Loeffler, J. S. (2006). Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nature Clinical Practice. Oncology, 3, 24–40.PubMedCrossRef

74.

Wu, H.-C., Huang, C.-T., & Chang, D.-K. (2008). Anti-angiogenic therapeutic drugs fro treatment of human cancer. J Cancer Molecules, 4, 37–45.

75.

Mokart, D., Capo, C., Blache, J. L., Delpero, J. R., Houvenaeghel, G., Martin, C., et al. (2002). Early postoperative compensatory anti-inflammatory response syndrome is associated with septic complications after major surgical trauma in patients with cancer. The British Journal of Surgery, 89, 1450–1456.PubMedCrossRef

76.

Bower, J. E., Ganz, P. A., Aziz, N., & Fahey, J. L. (2002). Fatigue and proinflammatory cytokine activity in breast cancer survivors. Psychosomatic Medicine, 64, 604–611.PubMed

77.

Rutkowski, P., Kaminska, J., Kowalska, M., Ruka, W., & Steffen, J. (2003). Cytokine and cytokine receptor serum levels in adult bone sarcoma patients: correlations with local tumor extent and prognosis. Journal of Surgical Oncology, 84, 151–159.PubMedCrossRef

78.

Fujiwaki, R., Iida, K., Nakayama, K., Kanasaki, H., Hata, K., Katabuchi, H., et al. (2003). Clinical significance of interleukin-1 receptor antagonist in patients with cervical carcinoma. Gynecologic Oncology, 89, 77–83.PubMedCrossRef

79.

Schmid, I., Schmitt, M., Streiter, M., Meilbeck, R., Haas, R. J., & Stachel, D. K. (2005). Effects of soluble TNF receptor II (sTNF-RII), IL-1 receptor antagonist (IL-1ra), tumor load and hypermetabolism on malnutrition in children with acute leukemia. European Journal of Medical Research, 10, 457–461.PubMed

80.

Laurencet, F. M., Chapuis, B., Roux-Lombard, P., Dayer, J. M., & Beris, P. (1994). Malignant histiocytosis in the leukaemic stage: a new entity (M5c-AML) in the FAB classification? Leukemia, 8, 502–506.PubMed

81.

Barak, V., Nisman, B., Polliack, A., Vannier, E., & Dinarello, C. A. (1998). Correlation of serum levels of interleukin-1 family members with disease activity and response to treatment in hairy cell leukemia. European Cytokine Network, 9, 33–39.PubMed

82.

Ito, H., & Miki, C. (1999). Profile of circulating levels of interleukin-1 receptor antagonist and interleukin-6 in colorectal cancer patients. Scandinavian Journal of Gastroenterology, 34, 1139–1143.PubMedCrossRef

83.

Tao, M., Li, B., Nayini, J., Andrews, C. B., Huang, R. W., Devemy, E., et al. (2000). SCF, IL-1beta, IL-1ra and GM-CSF in the bone marrow and serum of normal individuals and of AML and CML patients. Cytokine, 12, 699–707.PubMedCrossRef

84.

Kaminska, J., Kowalska, M. M., Nowacki, M. P., Chwalinski, M. G., Rysinska, A., & Fuksiewicz, M. (2000). CRP, TNF-alpha, IL-1ra, IL-6, IL-8 and IL-10 in blood serum of colorectal cancer patients. Pathology Oncology Research, 6, 38–41.PubMedCrossRef

85.

Orre, I. J., Murison, R., Dahl, A. A., Ueland, T., Aukrust, P., & Fossa, S. D. (2009). Levels of circulating interleukin-1 receptor antagonist and C-reactive protein in long-term survivors of testicular cancer with chronic cancer-related fatigue. Brain, Behavior, and Immunity, 23, 868–874.PubMedCrossRef

86.

Niedzwiecki, S., Stepien, T., Kuzdak, K., Stepien, H., Krupinski, R., Seehofer, D., et al. (2008). Serum levels of interleukin-1 receptor antagonist (IL-1ra) in thyroid cancer patients. Langenbeck's Archives of Surgery, 393, 275–280.PubMedCrossRef

87.

Poch, B., Lotspeich, E., Ramadani, M., Gansauge, S., Beger, H. G., & Gansauge, F. (2007). Systemic immune dysfunction in pancreatic cancer patients. Langenbeck's Archives of Surgery, 392, 353–358.PubMedCrossRef

88.

Ebrahimi, B., Tucker, S. L., Li, D., Abbruzzese, J. L., & Kurzrock, R. (2004). Cytokines in pancreatic carcinoma: correlation with phenotypic characteristics and prognosis. Cancer, 101, 2727–2736.PubMedCrossRef

89.

Graziano, F., Ruzzo, A., Santini, D., Humar, B., Tonini, G., Catalano, V., et al. (2005). Prognostic role of interleukin-1beta gene and interleukin-1 receptor antagonist gene polymorphisms in patients with advanced gastric cancer. Journal of Clinical Oncology, 23, 2339–2345.PubMedCrossRef

90.

Mustea, A., Pirvulescu, C., Konsgen, D., Braicu, E. I., Yuan, S., Sun, P., et al. (2008). Decreased IL-1 RA concentration in ascites is associated with a significant improvement in overall survival in ovarian cancer. Cytokine, 42, 77–84.PubMedCrossRef

91.

Bruserud, O., Aasen, I., Akselsen, P. E., Bergheim, J., Rasmussen, G., & Nesthus, I. (1996). Interleukin 1 receptor antagonist (IL1RA) in acute leukaemia: IL1RA is both secreted spontaneously by myelogenous leukaemia blasts and is a part of the acute phase reaction in patients with chemotherapy-induced leucopenia. European Journal of Haematology, 57, 87–95.PubMedCrossRef

92.

Gherardi, R. K., Belec, L., Soubrier, M., Malapert, D., Zuber, M., Viard, J. P., et al. (1996). Overproduction of proinflammatory cytokines imbalanced by their antagonists in POEMS syndrome. Blood, 87, 1458–1465.PubMed

93.

Iwagaki, H., Hizuta, A., & Tanaka, N. (1997). Interleukin-1 receptor antagonists and other markers in colorectal cancer patients. Scandinavian Journal of Gastroenterology, 32, 577–581.PubMedCrossRef

94.

Parekh, D. J., Ankerst, D. P., Baillargeon, J., Higgins, B., Platz, E. A., Troyer, D., et al. (2007). Assessment of 54 biomarkers for biopsy-detectable prostate cancer. Cancer Epidemiology, Biomarkers & Prevention, 16, 1966–1972.CrossRef

95.

Masters, S. L., Simon, A., Aksentijevich, I., & Kastner, D. L. (2009). Horror autoinflammaticus: the molecular pathophysiology of autoinflammatory disease (*). Annual Review of Immunology, 27, 621–668.PubMedCrossRef

96.

Mitroulis, I., Papadopoulos, V. P., Konstantinidis, T., & Ritis, K. (2008). Anakinra suppresses familial Mediterranean fever crises in a colchicine-resistant patient. The Netherlands Journal of Medicine, 66, 489–491.PubMed

97.

Calligaris, L., Marchetti, F., Tommasini, A., & Ventura, A. (2008). The efficacy of anakinra in an adolescent with colchicine-resistant familial Mediterranean fever. European Journal of Pediatrics, 167, 695–696.PubMedCrossRef

98.

Bodar, E. J., Simon, A., de Visser, M., & van der Meer, J. W. (2009). Complete remission of severe idiopathic cold urticaria on interleukin-1 receptor antagonist (anakinra). The Netherlands Journal of Medicine, 67, 302–305.PubMed

99.

Bodar, E. J., van der Hilst, J. C., Drenth, J. P., van der Meer, J. W., & Simon, A. (2005). Effect of etanercept and anakinra on inflammatory attacks in the hyper-IgD syndrome: introducing a vaccination provocation model. The Netherlands Journal of Medicine, 63, 260–264.PubMed

100.

Rigante, D., Ansuini, V., Bertoni, B., Pugliese, A. L., Avallone, L., Federico, G., et al. (2006). Treatment with anakinra in the hyperimmunoglobulinemia D/periodic fever syndrome. Rheumatology International, 27, 97–100.PubMedCrossRef

101.

Cailliez, M., Garaix, F., Rousset-Rouviere, C., Bruno, D., Kone-Paut, I., Sarles, J., et al. (2006). Anakinra is safe and effective in controlling hyperimmunoglobulinaemia D syndrome-associated febrile crisis. Journal of Inherited Metabolic Disease, 29, 763.PubMedCrossRef

102.

Fitzgerald, A. A., Leclercq, S. A., Yan, A., Homik, J. E., & Dinarello, C. A. (2005). Rapid responses to anakinra in patients with refractory adult-onset Still's disease. Arthritis and Rheumatism, 52, 1794–1803.PubMedCrossRef

103.

Lequerre, T., Quartier, P., Rosellini, D., Alaoui, F., De Bandt, M., Mejjad, O., et al. (2008). Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France. Annals of the Rheumatic Diseases, 67, 302–308.PubMedCrossRef

104.

Ohlsson, V., Baildam, E., Foster, H., Jandial, S., Pain, C., Strike, H., et al. (2008). Anakinra treatment for systemic onset juvenile idiopathic arthritis (SOJIA). Rheumatology (Oxford), 47, 555–556.CrossRef

105.

Mirkinson, L. J., Nagle, D., Kadom, N., & Jones, O. Y. (2006). Anakinra therapy in a child with systemic-onset juvenile rheumatoid arthritis after human herpesvirus 6 encephalitis. Journal of Clinical Rheumatology, 12, 83–86.PubMedCrossRef

106.

Botsios, C., Sfriso, P., Furlan, A., Punzi, L., & Dinarello, C. A. (2008). Resistant Behçet disease responsive to anakinra. Annals of Internal Medicine, 149, 284–286.PubMed

107.

De Koning HD, Bodar EJ, Simon A, van der Hilst JCH, Netea MG, Van der Meer JW (2005) Beneficial response to anakinra and thalidomide in Schnitzler's syndrome. Ann Rheum Dis, J. C. H

108.

Eiling, E., Moller, M., Kreiselmaier, I., Brasch, J., & Schwarz, T. (2007). Schnitzler syndrome: treatment failure to rituximab but response to anakinra. Journal of the American Academy of Dermatology, 57, 361–364.PubMedCrossRef

109.

Adam, Z., Krejci, M., Pour, L., Neubauer, J., Prasek, J., & Hajek, R. (2008). Schnitzler syndrome–report on a fourteen-year course of the disease and an overview of information on the disease. Vnitrní Lékarství, 54, 1140–1153.PubMed

110.

Simon, A., Bodar, E. J., van der Hilst, J. C. H., Van der Meer, J. W., Fiselier, T. J. W., Cuppen, M. P. J. M., et al. (2004). Beneficial response to interleukin-1 receptor antagonist in TRAPS. The American Journal of Medicine, 117, 208–210.PubMedCrossRef

111.

Sacre, K., Brihaye, B., Lidove, O., Papo, T., Pocidalo, M. A., Cuisset, L., et al. (2008). Dramatic improvement following interleukin 1beta blockade in tumor necrosis factor receptor-1-associated syndrome (TRAPS) resistant to anti-TNF-alpha therapy. The Journal of Rheumatology, 35, 357–358.PubMed

112.

Gattorno, M., Pelagatti, M. A., Meini, A., Obici, L., Barcellona, R., Federici, S., et al. (2008). Persistent efficacy of anakinra in patients with tumor necrosis factor receptor-associated periodic syndrome. Arthritis and Rheumatism, 58, 1516–1520.PubMedCrossRef

113.

Brenner, M., Ruzicka, T., Plewig, G., Thomas, P., & Herzer, P. (2009). Targeted treatment of pyoderma gangrenosum in PAPA (pyogenic arthritis, pyoderma gangrenosum and acne) syndrome with the recombinant human interleukin-1 receptor antagonist anakinra. The British Journal of Dermatology, 161, 1199–1201.PubMedCrossRef

114.

Kelly, A., & Ramanan, A. V. (2008). A case of macrophage activation syndrome successfully treated with anakinra. Nature Clinical Practice. Rheumatology, 4, 615–620.PubMedCrossRef

115.

Chou, R. C., Dinarello, C. A., Ferry, J. A., & Dal Cin, P. (2010). A 36-year-old woman with recurrent high-grade fevers, hypotension, and hypertriglyceridemia. Arthritis Care and Research, 62, 137–140.

116.

Botsios, C., Sfriso, P., Punzi, L., & Todesco, S. (2007). Non-complementaemic urticarial vasculitis: Successful treatment with the IL-1 receptor antagonist, anakinra. Scandinavian Journal of Rheumatology, 36, 236–237.PubMedCrossRef

117.

Furlan, A., Botsios, C., Ruffatti, A., Todesco, S., & Punzi, L. (2008). Antisynthetase syndrome with refractory polyarthritis and fever successfully treated with the IL-1 receptor antagonist, anakinra: a case report. Joint, Bone, Spine, 75, 366–367.PubMedCrossRef

118.

Chauffier, K., London, J., Beaudouin, C., & Fautrel, B. (2009). Indications of anakinra. La Presse Médicale, 38, 799–807.PubMedCrossRef

119.

So, A., De Smedt, T., Revaz, S., & Tschopp, J. (2007). A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Research & Therapy, 9, R28.CrossRef

120.

Terkeltaub, R., Sundy, J. S., Schumacher, H. R., Murphy, F., Bookbinder, S., Biedermann, S., et al. (2009). The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study. Annals of the Rheumatic Diseases, 68, 1613–1617.PubMedCrossRef

121.

Singh, D., & Huston, K. K. (2009). IL-1 inhibition with anakinra in a patient with refractory gout. Journal of Clinical Rheumatology, 15, 366.PubMedCrossRef

122.

Gratton, S. B., Scalapino, K. J., & Fye, K. H. (2009). Case of anakinra as a steroid-sparing agent for gout inflammation. Arthritis and Rheumatism, 61, 1268–1270.PubMedCrossRef

123.

McGonagle, D., Tan, A. L., Shankaranarayana, S., Madden, J., Emery, P., & McDermott, M. F. (2007). Management of treatment resistant inflammation of acute on chronic tophaceous gout with anakinra. Annals of the Rheumatic Diseases, 66, 1683–1684.PubMedCrossRef

124.

Abbate A, Kontos MC, Grizzard JD, Biondi-Zoccai GL, Van Tassell BW, Robati R, Roach LM, Arena RA, Roberts CF, Varma A, Gelwix C, Salloum FN, Hastillo A, Dinarello CA, Vetrovec GW (2010) Interleukin-1 blockade with anakinra to prevent adverse cardiac remodeling following acute myocardial infarction. Am J Cardiology in press

125.

Chevalier, X., Goupille, P., Beaulieu, A. D., Burch, F. X., Bensen, W. G., Conrozier, T., et al. (2009). Intraarticular injection of anakinra in osteoarthritis of the knee: a multicenter, randomized, double-blind, placebo-controlled study. Arthritis and Rheumatism, 61, 344–352.PubMedCrossRef

Title: Why not treat human cancer with interleukin-1 blockade?
Author: Charles A. Dinarello
Publication date: 01-06-2010
Publisher: Springer US
Published in: Cancer and Metastasis Reviews / Issue 2/2010
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI: https://doi.org/10.1007/s10555-010-9229-0

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2010

Metastasis: cancer cell’s escape from oxidative stress

Hypoxia, inflammation, and the tumor microenvironment in metastatic disease

TGFβ and cancer metastasis: an inflammation link

Hereditary ovarian cancers: from BRCA mutations to clinical management. A modern appraisal

Biography—Alberto Mantovani, MD

Bacterial infections associated with cancer: possible implication in etiology with special reference to lateral gene transfer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer